BRCA1 and prostate carcinoma: With respect to cancer therapy, PARP inhibitors are effective treatments for ovarian, breast, pancreatic, and prostate cancers with mutations in BRCA1 or BRCA2 (Fong et al, 2009; Tutt et al, 2021).